An Open-Label, Randomized, 4-Period, 4-Treatment, Crossover, Single-Center, Single-Dose Bioavailability Study With Alternate Methods of Administration of Crushed Naloxegol Tablets, 25 mg and of a Naloxegol Solution Formulation, 25 mg, Compared to Whole Naloxegol Tablets, 25 mg, in Healthy Subjects

Trial Profile

An Open-Label, Randomized, 4-Period, 4-Treatment, Crossover, Single-Center, Single-Dose Bioavailability Study With Alternate Methods of Administration of Crushed Naloxegol Tablets, 25 mg and of a Naloxegol Solution Formulation, 25 mg, Compared to Whole Naloxegol Tablets, 25 mg, in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Naloxegol (Primary)
  • Indications Constipation
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Jun 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
    • 21 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top